<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01040026</url>
  </required_header>
  <id_info>
    <org_study_id>NK_MM_01</org_study_id>
    <nct_id>NCT01040026</nct_id>
  </id_info>
  <brief_title>Expanded Natural Killer (NK) Cells for Multiple Myeloma Study</brief_title>
  <official_title>A Phase I/II Single Center Study to Assess Tolerability and Feasibility of Infusions of Allogeneic Expanded Haploidentical Natural Killer (NK) Cells in Patients Treated With High Dose Melphalan Chemotherapy and Autologous Stem Cell Transplantation for a Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High-dose chemotherapy with melphalan and autologous hematopoietic stem cell transplantation&#xD;
      (HSCT) is considered standard treatment for patients with multiple myeloma. While autologous&#xD;
      HSCT may induce remission in patients resistant to standard chemotherapy, and has been shown&#xD;
      to lead to long-lasting disease control in a subgroup of patients, the procedure is not&#xD;
      curative. Given enough time and in the absence of a competing cause of death, all patients&#xD;
      eventually relapse after auto-HSCT.&#xD;
&#xD;
      The only potentially curative approach currently available in the treatment of multiple&#xD;
      myeloma (MM) is stem cell trans-plantation from an allogeneic donor. Allogeneic HSCT&#xD;
      eradicates residual myeloma cells through T-cell mediated graft-versus-tumor effects.&#xD;
      Allogeneic HSCT is, however, associated with significant risk of graft-versus-host disease&#xD;
      and its use is therefore limited to younger patients with high risk dis-ease. Malignant&#xD;
      plasma cells in multiple myeloma are also sensitive to natural killer cell lysis. Natural&#xD;
      killer cells do not cause graft-versus-host disease, which has led to interest in their&#xD;
      therapeutic use in patients with multiple myeloma.&#xD;
&#xD;
      We have previously shown that immunomagnetic separation of a highly pure NK cell product from&#xD;
      a leukapheresis is possible and that these cells can be expanded up to 100-fold in a&#xD;
      GMP-compatible setting. The current study aims to test the tolerability and feasibility of&#xD;
      infusions of in vitro expanded haploidentical NK cells for patients after melphalan 200mg/m2&#xD;
      high dose chemotherapy and autologous HSCT in 10 patients. If feasible, the data will provide&#xD;
      a basis for further prospective studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of expanded NK cell infusion</measure>
    <time_frame>One year after infusion.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment efficacy</measure>
    <time_frame>One year after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>NK cell infusions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 NK cell infusions day 3-30; Treatment with in vitro expanded haploidentical NK cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment with in vitro expanded haploidentical NK cells</intervention_name>
    <description>10 expanded NK-DLI will be applied at fixed intervals and to each patient within 30 days (3 applications per week, Mo/We/Fr) starting with increasing CD56+CD3- NK cell doses at 3 dose levels (1.5x10e6/kg, 1.5x10e7/kg and 1x10e8/kg) and, if safe, continuing with maximally 7 doses of 1x10e8/kg. Maximal cumulative T-cell dose is fixed at &lt;1x10e5/kg</description>
    <arm_group_label>NK cell infusions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 years, with multiple myeloma and indication for an autologous HSCT&#xD;
&#xD;
          -  Available related haploidentical donor&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for autologous/allogeneic tandem HSCT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jakob Passweg, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Hematology, Petersgraben 4, CH-4031 Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 23, 2009</study_first_submitted>
  <study_first_submitted_qc>December 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2009</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

